Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of LY3143753 and LY3185643 in Healthy Subjects
NCT02342314Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2015
- Primary completion
- Sep 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3143753 and LY3185643 in hypoglycemia (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Jan 2015; status: completed.
02
Drugs
LY3143753LY3185643
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT02342314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342314.